Aclaris 制药

Aclaris Therapeutics Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 22% premium over our quantitative fair value estimate of $2.77 per share; however, this estimate should be taken with a pinch of salt due to its extreme uncertainty rating.

The firm's lack of profitability undermines our estimated valuation. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's sales yield of 1.4% lies in the bottom 10% compared with peers globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which contributes to our view that shares are expensive.

The company's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 20.3%, for example, ranks in the bottom 20% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.